LU92577B1 - Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose - Google Patents

Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose

Info

Publication number
LU92577B1
LU92577B1 LU92577A LU92577A LU92577B1 LU 92577 B1 LU92577 B1 LU 92577B1 LU 92577 A LU92577 A LU 92577A LU 92577 A LU92577 A LU 92577A LU 92577 B1 LU92577 B1 LU 92577B1
Authority
LU
Luxembourg
Prior art keywords
treatment
pharmaceutical compositions
cystic fibrosis
new compounds
compounds
Prior art date
Application number
LU92577A
Other languages
English (en)
Inventor
Martin James Inglis Andrews
Sebastien Jean-Jacques Cedric Dropsit-Montovert
Hans Kelgtermans
Sebastien Laurent Xavier Martina
Steven Emiel Van Der Plas
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51300734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92577(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201317935A external-priority patent/GB201317935D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of LU92577B1 publication Critical patent/LU92577B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LU92577A 2013-08-08 2014-08-05 Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose LU92577B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13179671 2013-08-08
GB201317935A GB201317935D0 (en) 2013-10-10 2013-10-10 Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
PCT/EP2014/066806 WO2015018823A1 (fr) 2013-08-08 2014-08-05 Thiéno [2,3-c] pyrannes utilisés en tant que modulateurs du cftr

Publications (1)

Publication Number Publication Date
LU92577B1 true LU92577B1 (fr) 2015-02-24

Family

ID=51300734

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92577A LU92577B1 (fr) 2013-08-08 2014-08-05 Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose

Country Status (32)

Country Link
US (4) US9133210B2 (fr)
EP (2) EP3486246A1 (fr)
JP (1) JP6425724B2 (fr)
KR (1) KR20160040295A (fr)
CN (1) CN105658655B (fr)
AU (1) AU2014304562B8 (fr)
BR (1) BR112016001984A2 (fr)
CA (1) CA2919776A1 (fr)
CL (1) CL2016000298A1 (fr)
CR (1) CR20160119A (fr)
CY (1) CY1121027T1 (fr)
DK (1) DK3030568T3 (fr)
DO (1) DOP2016000041A (fr)
ES (1) ES2691944T3 (fr)
HR (1) HRP20181541T1 (fr)
HU (1) HUE040366T2 (fr)
IL (1) IL243600B (fr)
LT (1) LT3030568T (fr)
LU (1) LU92577B1 (fr)
MX (1) MX2016001602A (fr)
MY (1) MY176814A (fr)
PE (1) PE20160286A1 (fr)
PH (1) PH12016500161A1 (fr)
PL (1) PL3030568T3 (fr)
PT (1) PT3030568T (fr)
RU (1) RU2708690C2 (fr)
SG (1) SG11201600891UA (fr)
SI (1) SI3030568T1 (fr)
TR (1) TR201819434T4 (fr)
TW (1) TWI649325B (fr)
UY (1) UY35700A (fr)
WO (1) WO2015018823A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
JP6425724B2 (ja) 2013-08-08 2018-11-21 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
KR20180029204A (ko) 2015-06-02 2018-03-20 애브비 에스.에이.알.엘. 치환된 피리딘 및 사용 방법
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
EP3359539A1 (fr) 2015-10-09 2018-08-15 AbbVie S.À.R.L. Acides pyrazolo[3,4-b]pyridin-6-carboxyliques substitués et leur utilisation
US20170100374A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Potentiator-corrector combinations useful in the treatment of cystic fibrosis
WO2017060879A1 (fr) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Nouveaux composés destinés au traitement de la fibrose kystique
ES3066112T3 (en) 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
AU2017217806A1 (en) * 2016-02-12 2018-08-16 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified CFTR modulators
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018073175A1 (fr) 2016-10-17 2018-04-26 AbbVie S.à.r.l. Composés et compositions pharmaceutiques associées, destinés à être utilisés dans le traitement de la mucoviscidose
WO2018116185A1 (fr) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Modulateurs cftr deutérés et procédés d'utilisation
KR20190098204A (ko) * 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
EP3672598A4 (fr) 2017-08-24 2021-04-28 The Regents of The University of California Compositions pharmaceutiques oculaires
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
WO2019193062A1 (fr) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Pyrrolidines substituées et leur utilisation
AU2019291111B9 (en) * 2018-06-21 2023-08-24 UCB Biopharma SRL Thiophene derivatives for the treatment of disorders caused by IgE
CN108546266B (zh) * 2018-07-25 2020-09-22 上海毕得医药科技有限公司 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (fr) 2019-07-12 2021-01-21 Orphomed, Inc. Composé pour le traitement de la fibrose kystique
CA3157798A1 (fr) 2019-11-12 2021-05-20 Zhongli Gao Heteroarylaminosulfonamides a 6 chainons pour le traitement de maladies et d'etats medies par une activite cftr deficiente
WO2021113806A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2021113809A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
IL300405A (en) 2020-08-20 2023-04-01 Univ Leland Stanford Junior Methods for treating respiratory diseases characterized by excessive secretion of mucus
WO2022150173A1 (fr) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
EP4274828A1 (fr) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulateurs de la protéine régulatrice de la conductance transmembranaire fibrokystique et méthodes d'utilisation
EP4396179A1 (fr) 2021-09-03 2024-07-10 Genzyme Corporation Composés indoles et procédés d'utilisation
WO2023034946A1 (fr) 2021-09-03 2023-03-09 Genzyme Corporation Composés indoles et leurs utilisations dans le traitement de la fibrose kystique
US12072466B1 (en) * 2021-09-30 2024-08-27 Zoox, Inc. Detecting dark objects in stray light halos
JP2025519597A (ja) * 2022-06-10 2025-06-26 シオナ セラピューティクス インコーポレイテッド 化合物、組成物、及びそれらを使用する方法
WO2024054845A1 (fr) 2022-09-07 2024-03-14 Sionna Therapeutics Composés macrocycliques, compositions et leurs procédés d'utilisation
AU2023338225A1 (en) 2022-09-07 2025-03-20 Genzyme Corporation Macrocyclic compounds, compositions, and methods of using thereof
WO2024054851A1 (fr) 2022-09-07 2024-03-14 Sionna Therapeutics Composés macrocycliques, compositions et méthodes d'utilisation associées
WO2025132358A1 (fr) 2023-12-21 2025-06-26 Galapagos Nv Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies infectieuses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
JP3409029B2 (ja) 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
EP1080068A1 (fr) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulateurs de proteine tyrosine phosphatases
IT1313581B1 (it) 1999-07-30 2002-09-09 Recordati Chem Pharm Derivati tienopirancarbossamidici.
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
JP2002308870A (ja) 2001-04-11 2002-10-23 Rrf Kenkyusho:Kk チオフェン骨格を有する抗菌剤
CN1668308A (zh) 2002-07-29 2005-09-14 兰贝克赛实验室有限公司 作为抗菌剂的噁唑烷酮衍生物
JP2004137185A (ja) 2002-10-17 2004-05-13 Rrf Kenkyusho:Kk チオフェン骨格を有する抗菌剤
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2005023818A2 (fr) 2003-09-10 2005-03-17 Gpc Biotech Ag Composes heterobicycliques en tant qu'agents actifs au niveau pharmaceutique
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20070010537A1 (en) 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
WO2006044826A2 (fr) 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Compositions et leur utilisation en tant qu'agents antitumoraux
MX2007007026A (es) 2004-12-17 2007-07-04 Hoffmann La Roche Derivados de tieno-piridina como intensificadores alostericos de gaba-b.
AU2007214709A1 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2007139795A1 (fr) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophène-carboxamides inhibiteurs des protéines kinases
TW200817385A (en) 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
ES2581386T3 (es) 2008-02-25 2016-09-05 Merck Patent Gmbh Activadores de la glucoquinasa
GB0813873D0 (en) 2008-07-30 2008-09-03 Univ Dundee Compounds
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
US20120136003A1 (en) 2009-04-20 2012-05-31 Institute For Oneworld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2011097607A1 (fr) 2010-02-08 2011-08-11 Southern Research Institute Traitement antiviral et dosage pour cribler des antiviraux
US20130072473A1 (en) * 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
CN103906741B (zh) 2011-10-27 2016-01-20 安斯泰来制药株式会社 氨烷基取代的n-噻吩基苯甲酰胺衍生物
WO2013129435A1 (fr) 2012-02-28 2013-09-06 協和発酵キリン株式会社 Dérivé de thiophène fusionné
UA115666C2 (uk) 2012-07-12 2017-12-11 Ніссан Кемікал Індастріз, Лтд. Заміщена оксимом амідна сполука і засіб для боротьби зі шкідниками
WO2014052914A1 (fr) 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Composés et procédés de prévention, de traitement et/ou de protection contre la mort de cellules ciliées sensorielles
JP6425724B2 (ja) * 2013-08-08 2018-11-21 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン

Also Published As

Publication number Publication date
DOP2016000041A (es) 2016-04-04
ES2691944T3 (es) 2018-11-29
RU2708690C2 (ru) 2019-12-11
MX2016001602A (es) 2016-12-15
US9351955B2 (en) 2016-05-31
AU2014304562A8 (en) 2018-07-05
CR20160119A (es) 2016-07-12
KR20160040295A (ko) 2016-04-12
BR112016001984A2 (pt) 2017-08-01
LT3030568T (lt) 2018-12-27
JP6425724B2 (ja) 2018-11-21
US20180221334A1 (en) 2018-08-09
HUE040366T2 (hu) 2019-03-28
SI3030568T1 (sl) 2019-02-28
RU2016107721A3 (fr) 2018-04-28
MY176814A (en) 2020-08-21
CL2016000298A1 (es) 2016-11-11
IL243600B (en) 2019-05-30
US20150045327A1 (en) 2015-02-12
US20160317493A1 (en) 2016-11-03
US10568867B2 (en) 2020-02-25
US9133210B2 (en) 2015-09-15
EP3030568B1 (fr) 2018-09-19
CY1121027T1 (el) 2019-12-11
PT3030568T (pt) 2018-12-24
AU2014304562B2 (en) 2018-05-17
IL243600A0 (en) 2016-02-29
SG11201600891UA (en) 2016-03-30
HRP20181541T1 (hr) 2018-11-16
CA2919776A1 (fr) 2015-02-12
EP3486246A1 (fr) 2019-05-22
AU2014304562B8 (en) 2018-07-05
HK1222861A1 (en) 2017-07-14
CN105658655A (zh) 2016-06-08
AU2014304562A1 (en) 2016-02-04
US20160022633A1 (en) 2016-01-28
TWI649325B (zh) 2019-02-01
DK3030568T3 (en) 2019-01-07
TW201536791A (zh) 2015-10-01
PE20160286A1 (es) 2016-05-22
WO2015018823A1 (fr) 2015-02-12
PH12016500161A1 (en) 2016-04-25
JP2016527296A (ja) 2016-09-08
CN105658655B (zh) 2018-11-13
RU2016107721A (ru) 2017-09-13
TR201819434T4 (tr) 2019-01-21
EP3030568A1 (fr) 2016-06-15
UY35700A (es) 2015-03-27
PL3030568T3 (pl) 2019-03-29
US9895347B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
LU92578B1 (fr) Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
FR24C1025I1 (fr) Compositions et méthodes de traitement de l'anémie
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3280421A4 (fr) Compositions pharmaceutiques pour thérapie combinée
EP2981551A4 (fr) Méthodes et compositions pour le traitement de la maladie de pompe
HUE053115T2 (hu) Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP2844346A4 (fr) Compositions pharmaceutiques pour traitement combiné
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EP2836226A4 (fr) Compositions et méthodes pour le traitement d'hémoglobinopathies
EP2827856A4 (fr) Composés et compositions pour le traitement d'affections musculaires
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP2852571A4 (fr) Compositions et méthodes pour le traitement de la mucosite
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
EP3378484A4 (fr) Composition pharmaceutique pour le traitement de la fibrose cardiaque
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3363450A4 (fr) Composition de médecine traditionnelle chinoise pour le traitement du psoriasis
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés